Ainos Reports First Quarter 2025 Financial Results
Rhea-AI Summary
Positive
- Revenue increased 412% YoY to $106,207, driven by AI Nose product sales
- Turned gross loss into gross profit of $87,974 in Q1
- Secured strategic partnerships with major companies in robotics (ugo) and semiconductor (ASE) sectors
- Received TFDA and IRB approvals for two VELDONA® clinical trials in Taiwan
- Obtained key invention patent in Japan for VELDONA® oral interferon formulation
Negative
- Revenue growth started from a relatively low base
- Increased non-cash SG&A expenses due to share-based compensation
- Additional R&D investments and financing needed for growth initiatives
Insights
Ainos reports small but explosive 412% revenue growth from AI Nose technology while pivoting from healthcare to industrial applications.
Ainos' Q1 results showcase an impressive
While the absolute revenue numbers remain extremely small for a publicly traded company, this early commercial traction validates their AI Nose technology's viability. The primary revenue driver was AI Nose products for elderly care under their NISD co-development project, showing modest product-market fit in healthcare applications.
More strategically important is Ainos' expansion beyond healthcare into higher-growth industrial segments through partnerships with ASE (semiconductor manufacturing) and ugo (robotics). These market expansions position the company at the intersection of two substantial growth markets: the electronic nose market (projected to grow from
The parallel advancement of two clinical trials for their VELDONA therapeutic program demonstrates capital efficiency and potential future revenue diversification. Despite increased non-cash SG&A expenses from share-based compensation, management indicates controlled operational spending.
The financial picture reveals a company in early commercialization with promising growth trajectory but requiring substantial scaling to reach meaningful revenue. Investors should view this as a high-risk, early-stage technology play with differentiated IP in the emerging digital scent recognition space, where modest early traction must be weighed against the need for significant future growth to justify its public market valuation.
Ainos' AI Nose technology creates first-mover advantage in the untapped olfactory AI segment with promising cross-industry applications.
Ainos' AI Nose technology addresses a fascinating gap in the sensory capabilities of current AI and robotics systems—the sense of smell. While vision and audio processing are well-established in AI systems, olfactory sensing remains largely unexplored, creating a genuine differentiation opportunity in an otherwise crowded AI market.
The technical foundation of their platform combines MEMS gas sensors with proprietary AI algorithms to create "Smell IDs" from airborne chemical compounds. This builds a digital representation of scents that can be processed by machines—essentially creating a machine-readable language for odors. The technology's architecture enables deployment across multiple hardware platforms, as evidenced by their integration into both healthcare products and robotic systems.
Their strategic partnerships reveal a thoughtful go-to-market strategy. By partnering with ugo for robotics applications, they're embedding their technology into established platforms rather than attempting to build their own hardware. Similarly, the ASE collaboration targets the semiconductor manufacturing space—an industry with well-defined air quality and chemical detection needs where improved olfactory sensing offers clear operational value.
The technology's versatility across healthcare (elderly care, disease detection), industrial (semiconductor manufacturing), and consumer robotics suggests strong platform potential. However, each vertical requires specialized development, tuning sensory parameters and response logic for different use cases as mentioned in their ugo integration update.
The development of a broader "Ainos Alliance" indicates an ecosystem approach, suggesting they view their technology as a platform play rather than just a product. This platform strategy, if successful, could position Ainos as a foundational technology provider in the emerging field of digital scent recognition, creating a defensible position in an AI subtechnology with significant runway for growth.
Q1 revenues increased
Delivers strong turnaround from gross loss to gross profit in Q1
AI Nose gains traction beyond healthcare with strategic partnerships in robotics and semiconductor sectors
VELDONA® program advances with TFDA and IRB Approvals for two clinical trials in Taiwan
SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 12, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company") today announced its financial results for the first quarter ended March 31, 2025.
Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Q1 2025 represents a significant step forward in advancing our long-term strategy to build a differentiated healthcare and technology company powered by scent digitization, AI-enhanced diagnostics and innovative therapeutics. Revenues increased
"While our AI Nose technology has a deep root in healthcare use-case, we are expanding the application scope into the robotics and industrial sectors. We've made rapid progress in establishing strategic partnerships, including collaborations with a leading Japanese service robot developer to embed AI Nose into robots, and with the world's largest semiconductor packaging and testing provider to deploy AI Nose in semiconductor manufacturing environments. "
"Rising AI integration across industries validates our strategic direction. The global electronic nose market is projected to grow from
"The U.S. Treasury Secretary recently emphasized the need for American leadership in AI and quantum technologies. At Ainos, we share this vision. Our AI-powered electronic nose addresses one of the untapped frontiers in AI and robotics-smell. While machines can see and hear, olfaction remains the missing sense. By pioneering digital scent, Ainos is unlocking a vital layer of perception for the next generation of intelligent systems."
"As a U.S.-based innovator, we're focused on scaling AI-powered smelltech sensing with deep R&D, IP expansion, and strategic long-term growth. While our first-quarter revenue grew from a low base, it reflects early traction for our breakthrough technology. With the AI market projected to reach
"At the same time, we've reached key milestones in VELDONA®, our low-dose interferon therapeutics program, securing Taiwan Food and Drug Administration ("TFDA") approval for initiating a clinical trial targeting HIV oral warts, and Institutional Review Board ("IRB") clearance from Taipei Medical University for a clinical trial targeting primary Sjögren's syndrome. Our launch two trials in parallel is a further demonstration of our capital-efficient approach, operational discipline, and commitment to developing innovative, patient-friendly therapies for rare and underserved indications."
"Looking ahead, we remain focused on execution and strategic partnerships that can accelerate commercialization and global reach. We are encouraged by the momentum we've built and the opportunities that lie ahead. We believe that our leading AI Nose technology and immunotherapy-combined with our agility and vision-position Ainos to unlock vast growth potential and deliver sustained shareholder value."
Christopher Lee, Chief Financial Officer of Ainos, remarked, "We saw the early financial benefits of our strategic shift in Q1. Thanks to our AI Nose products, revenues increased
Recent Business Developments
On April 30, 2025, Ainos formed a strategic partnership with ASE Chung Li ("ASECL"), a key site of Advanced Semiconductor Engineering, Inc. (ASE), the world's leading provider of semiconductor assembly and test services. This partnership entails Ainos and ASECL to explore deploying the AI Nose across semiconductor manufacturing scenarios for improved real-time air quality monitoring, predictive maintenance, energy efficiency, precision process control, and yield optimization.
On April 21, 2025, Ainos announced the successful installation of its proprietary AI Nose olfaction module on a robot developed by ugo, Inc. ("ugo"), Japan's leading service robotics company. This installation marks a major milestone in multisensory robotics, paving the way for real-world applications. The Company and ugo are now entering the next phase of critical development, focusing on user interface (UI) design and backend control system integration and tuning of sensory parameters and response logic, expected to be completed within 2 to 4 weeks.
On April 14, 2025, Ainos secured approval from TFDA clearance for initiating clinical trials using its next-generation VELDONA® formulation for treating HIV-related oral warts. The Company also received IRB clearance from Taipei Medical University for a clinical trial targeting primary Sjögren's syndrome (pSS) with VELDONA® formulation.
On March 11, 2025, the Company formed a strategic partnership with Advanced Semiconductor Engineering, Inc., the world's largest provider of semiconductor packaging and testing services. The collaboration aims to transform semiconductor manufacturing by incorporating Ainos' patented AI Nose technology to analyze airborne chemicals into "Smell IDs," thereby enhancing process efficiency, environmental safety, and ESG compliance.
On March 5, 2025, the Company entered a strategic partnership with ugo, Inc., Japan's leading service robotics provider, to integrate its AI Nose technology into ugo's robotic platform. This collaboration introduces olfactory perception to robots, enabling AI-driven scent detection for deployment across healthcare, industrial, and public security sectors-addressing labor shortages with intelligent automation.
On January 27, 2025, the Company announced that it had received a key invention patent in Japan for its oral interferon formulation, VELDONA®, targeting the treatment and prevention of coronavirus infections. With this grant, Ainos strengthens its global IP portfolio and advances its commercialization plans in the
On January 13, 2025, Ainos announced its revolutionary AI Nose for robotics application and invited robotics companies worldwide to join the Ainos Alliance.Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose is redefining robotic interaction with various environments-unlocking transformative applications for the industrial, healthcare, and consumer sectors.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name "Ainos" combines "AI" and "Nose" to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Safe Harbor Statement
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Investor Relations Contact
Feifei Shen
Email: IR@ainos.com
Ainos, Inc.
Condensed Balance Sheets
(Unaudited)
March 31, | December 31, | |||||||
2025 | 2024 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 2,628,286 | $ | 3,892,919 | ||||
Accounts receivable | 91 | 56 | ||||||
Inventory, net | 141,831 | 143,756 | ||||||
Other current assets | 280,784 | 301,077 | ||||||
Total current assets | 3,050,992 | 4,337,808 | ||||||
Intangible assets, net | 22,633,161 | 23,748,328 | ||||||
Property and equipment, net | 494,387 | 559,645 | ||||||
Other assets | 174,536 | 174,418 | ||||||
Total assets | $ | 26,353,076 | $ | 28,820,199 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Contract liabilities | $ | - | $ | 106,329 | ||||
Convertible notes payable | 1,000,000 | 3,000,000 | ||||||
Accrued expenses and others current liabilities | 523,467 | 848,615 | ||||||
Total current liabilities | 1,523,467 | 3,954,944 | ||||||
Convertible notes payable - noncurrent | 11,000,000 | 9,000,000 | ||||||
Other long-term liabilities | 707,957 | 348,945 | ||||||
Total liabilities | 13,231,424 | 13,303,889 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, | - | - | ||||||
Common stock, | 172,152 | 154,274 | ||||||
Additional paid-in capital | 69,435,008 | 68,520,881 | ||||||
Accumulated deficit | (56,035,338 | ) | (52,749,316 | ) | ||||
Accumulated other comprehensive loss - translation adjustment | (450,170 | ) | (409,529 | ) | ||||
Total stockholders' equity | 13,121,652 | 15,516,310 | ||||||
Total liabilities and stockholders' equity | $ | 26,353,076 | $ | 28,820,199 | ||||
Ainos, Inc.
Condensed Statements of Operations
(Unaudited)
Three months ended March 31, | ||||||||
2025 | 2024 | |||||||
Revenues | $ | 106,207 | $ | 20,729 | ||||
Cost of revenues | (18,233 | ) | (26,754 | ) | ||||
Gross profit (loss) | 87,974 | (6,025 | ) | |||||
Operating expenses: | ||||||||
Research and development expenses | 1,724,084 | 2,084,648 | ||||||
Selling, general and administrative expenses | 1,526,761 | 1,029,418 | ||||||
Total operating expenses | 3,250,845 | 3,114,066 | ||||||
Loss from operations | (3,162,871 | ) | (3,120,091 | ) | ||||
Non-operating (expenses) income, net: | ||||||||
Interest expense | (180,445 | ) | (48,696 | ) | ||||
Issuance cost of senior secured convertible note measured at fair value | - | (138,992 | ) | |||||
Fair value change for senior secured convertible note | - | (31,568 | ) | |||||
Other income, net | 57,294 | 24,537 | ||||||
Total non-operating expenses, net | (123,151 | ) | (194,719 | ) | ||||
Net loss before income taxes | (3,286,022 | ) | (3,314,810 | ) | ||||
Provision for income taxes | - | - | ||||||
Net loss | $ | (3,286,022 | ) | $ | (3,314,810 | ) | ||
Net loss per common share - basic and diluted | $ | (0.21 | ) | $ | (0.57 | ) | ||
Weighted-average shares used in computing net loss per common share-basic and diluted | 15,863,060 | 5,771,283 | ||||||
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
What was Ainos (AIMD) revenue growth in Q1 2025?
What are the main strategic partnerships announced by Ainos (AIMD) in early 2025?
What is the market potential for Ainos (AIMD) electronic nose technology?
What progress has Ainos (AIMD) made with its VELDONA® therapeutic program?
How did Ainos (AIMD) perform financially in terms of profitability in Q1 2025?
